1	TITLE PAGE
2 3 4	DEVELOPING NEW DUAL-ACTION ANTIVIRAL/ANTI- INFLAMMATORY SMALL MOLECULES FOR COVID-19 TREATMENT USING IN SILICO AND IN-VITRO APPROACHES
5 6	Short Title: ANTIVIRAL AND ANTI-INFLAMMATORY SMALL MOLECULES FOR COVID- 19 TREATMENT
7	Vladimir V. Ivanov ¹ [†] , Anton B. Zakharov ¹ , Dmytro O. Anokhin ¹ , Olha O. Mykhailenko ² , Sergiy
8	M. Kovalenko ¹ , Larysa V. Yevsieieva ¹ , Victoriya A. Georgiyants ^{2*} , Michal Korinek ^{3,4} [†] , Yu-Li
9	Chen ⁵ , Shu-Yen Fang ^{4,6} , Mohamed El-Shazly ⁷ , Tsong-Long Hwang ^{4,5,8*} , Oleg M. Kalugin ¹
10 11 12 13	¹ School of Chemistry, V. N. Karazin Kharkiv National University, Kharkiv 61077, Ukraine. <u>vivanov@karazin.ua, https://orcid.org/0000-0003-2297-9048</u> (V.V.I.); <u>abzakharov@karazin.ua,</u> <u>https://orcid.org/0000-0002-9120-8469</u> (A.B.Z.); <u>dmitriy25102002@gmail.com,</u> <u>https://orcid.org/0000-0002-4958-2692</u> (D.O.A.);
14	sergiy.m.kovalenko@karazin.ua, <u>https://orcid.org/0000-0003-2222-8180</u> (S.M.K.);
15	lar0858@gmail.com, https://orcid.org/0000-0002-8427-7036 (L.V.Y); onkalugin@gmail.com,
16	https://orcid.org/0000-0003-3273-9259 (O.M.K.)
17	² Department of Pharmaceutical Chemistry, National University of Pharmacy, Kharkiv 61002,
18	Ukraine. o.mykhailenko@nuph.edu.ua; https://orcid.org/0000-0003-3822-8409 (O.O.M.);
19	vgeor@nuph.edu.ua; https://orcid.org/0000-0001-8794-8010 (V.A.G.)
20	³ Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University,
21	Kaohsiung 80708, Taiwan. michalk@kmu.edu.tw, https://orcid.org/0000-0002-8988-8610 (M.K.)
22	⁴ Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan
23	33302, Taiwan. d1001501@cgu.edu.tw (SY.F.),
24	⁵ Graduate Institute of Health Industry Technology and Research Center for Chinese Herbal
25	Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan
26	33303, Taiwan <u>oo66931@gmail.com</u> , https://orcid.org/0000-0003-2392-1702 (YL.C.);
27	htl@mail.cgust.edu.tw, https://orcid.org/0000-0002-5780-3977 (TL.H.),
28	⁶ Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan
29	33302, Taiwan.
30	⁷ Department of Pharmacognosy, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.
31	mohamed.elshazly@pharma.asu.edu.eg https://orcid.org/0000-0003-0050-8288 (M.E.S.)
32	⁸ Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan
33 34 35	* Corresponding authors: vgeor@nuph.edu.ua (VAG): htl@mail.cgu.edu.tw (TI.H.): Tel.: NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. +380572-67-91-97 (V.G.); +886-3-2118800 (ext. 5523) (TL.H.)

- 36 37
- [†] These authors contributed equally to this work
- 38

39 Abstract

40 This study aims to develop new molecular structures as potential therapeutic agents 41 against COVID-19, utilizing both in silico and in vitro studies. Potential targets of cepharanthine (CEP) against COVID-19 to reveal its underlying mechanism of action 42 43 were evaluated using *in silico* screening experiments. A library of new molecules was 44 docked into the receptor binding domain of the SARS-CoV-2 spike glycoprotein 45 complex with its receptor, human ACE2, to identify promising compounds. Receptor-46 oriented docking was performed using the most likely macromolecular targets, aimed 47 at inhibiting key viral replication pathways and reducing inflammatory processes in 48 damaged tissues. The hit molecules showed potential inhibition of Mpro and PLpro 49 proteases of SARS-CoV-2, which are involved in viral replication. They also showed 50 a potential inhibitory effect on Janus kinase (Jak3), which mediates intracellular 51 signaling responsible for inflammatory processes.

The *in vitro* study examined the effects of the selected hit molecules on the generation of superoxide anions and the release of elastase in activated neutrophils, which are factors that exacerbate tissue inflammation and worsen the clinical manifestations of COVID-19. It was demonstrated that 2-((5-((4-isopropylphenyl)sulfonyl)-6-oxo-1,6dihydropyrimidin-2-yl)thio)-N-(3-methoxyphenyl)acetamide (**Hit15**) inhibited virus infection by 43.0% at 10 μ M using pseudovirus assay and suppressed fMLF/CBinduced superoxide anion generation and elastase release in human neutrophils with

59 IC₅₀ values 1.43 and 1.28 μ M, respectively. Hit15 showed promising activity against

60 coronavirus that can be further developed into a therapeutic agent.

61 Keywords: synthetic compounds, viral entry and replication, spike, SARS-CoV-2,
62 neutrophils

63

64 Introduction

The recent trends in the search for effective drugs against COVID-19 focus on the development of inhibitors of key SARS-CoV-2 proteins. Integrating antiviral and antiinflammatory therapy is a critical approach to managing COVID-19 since the inflammation caused by the immune response leads to serious complications of the disease [1, 2].

70 Understanding the pathological progression and clinical manifestations of COVID-19 71 is a prerequisite for the development of drugs for rational therapeutic intervention. The 72 challenge of developing effective drugs to combat SARS-CoV-2 remains unresolved. 73 There is an urgent need for medications that can suppress the main mechanisms of 74 SARS-CoV-2 replication within the cell and mitigate the consequences of its impact 75 on the human body [3]. This need has become especially relevant with the emergence 76 of new viral variants capable of evading immune protection provided by vaccines [4, 77 5].

COVID-19, caused by the SARS-CoV-2 virus, is a complex, multi-organ, and
heterogeneous disease. The clinical manifestations of COVID-19 are diverse. The
disease can progress from uncomplicated forms to pneumonia and acute respiratory

81 distress syndrome (ARDS), requiring intensive care [6]. The pathogenesis of COVID-82 19 is driven by a hyperactive inflammatory response, leading to severe inflammation 83 and tissue damage, particularly in the lungs [7]. It is known that excessive neutrophil 84 activation causes tissue damage, and the neutrophil activation pathway plays a key role 85 in the poor prognosis of COVID-19 patients by exacerbating lung inflammation and 86 respiratory failure. Activated neutrophils secrete several cytokines, including superoxide anion, which can directly or indirectly cause tissue damage. Neutrophil 87 88 elastase is a major product secreted by activated neutrophils and a key factor in tissue 89 destruction in inflammatory diseases [8]. The inhibition of superoxide formation and 90 elastase release, which are the markers of the anti-inflammatory response, can reduce 91 the inflammatory burden and limit damage to the lungs and other tissues caused by COVID-19 [9]. 92

The integration of antiviral and anti-inflammatory therapies is a key approach to managing COVID-19. This approach was initially utilized, for example, with the introduction of corticosteroids into treatment regimens to reduce the body's inflammatory response [1, 2]. In this context, there is growing interest in biologically active substances from the plant *Jordanian hawksbeard*, as they possess both antiinflammatory and antiviral properties. These substances inhibited the main protease of SARS-CoV-2 and reduced inflammatory processes [8, 10].

Studies confirmed the *in vitro* and *in vivo* antiviral potential of cepharanthine (CEP)
against SARS-CoV-2. CEP demonstrated multiple molecular mechanisms, including
the suppression of the viral entry phase (by interacting with the viral spike protein and

103 blocking its binding to ACE2) and reducing the production of inflammatory factors104 [11, 12].

105 Approaches that enable the targeted creation of new pharmacologically active 106 molecules were implemented in previous studies including computer-aided molecular 107 modeling (CAMM) and QSAR methods [13]. In our search for new agents against 108 SARS-CoV-2, we used workflows that combine several tools, such as pharmacophore 109 screening of large chemical spaces and molecular docking of preselected candidates 110 [14]. 111 In this study, we used *in silico* screening experiments and receptor-oriented docking in 112 the receptor binding domain of the SARS-CoV-2 Omicron spike glycoprotein complex

113 with its receptor, human ACE2. We also used the three-dimensional structural models

114 of other active sites of biological molecules involved in the mechanisms of SARS-

115 CoV-2's impact on the body, using cepharanthine as a representative structure.

116

117 Materials and Methods

118 **Computational Procedures**

Molecular ligand analysis and the design of new biologically active molecules were performed using free and publicly available software packages including Jmol [15], PyMol [16], and LigandScout 4.4 [17, 18], which allowed for the pharmacophore analysis and virtual screening of specific molecular databases relative to the generated pharmacophore.

LigandScout tools [18] were used to identify the molecular parameters that would
correspond to drug-like properties. Molecules with poor permeability and oral
absorption (molecular weight > 500, C logP > 5, more than five hydrogen bond donors,
and more than ten acceptor groups) were excluded [19].
To understand the possible mechanisms of interaction between substances and
biological targets, we used the SwissTargetPrediction web server [20] to predict the

130 biological activity of small molecules. The DataWarrior program was employed to

131 calculate physicochemical properties and analyze molecular scaffolds [21].

132 **Preparation of Proteins and Database**

X-ray crystal structures of the target proteins were obtained from the Protein Data Bank
(PDB) [22] and used for virtual screening and receptor-oriented docking. Molecules
with properties matching the pharmacophore structure constituting a set of promising
molecules ("hits"), were used in the docking procedure with the active site of the
corresponding target protein.

For the *in silico* virtual screening, we used a chemical space of molecules containing more than 70,000 organic compounds. The compounds of this database (DB_KSM) were synthesized by the synthetic group of Prof. S.M. Kovalenko (Department of Organic Chemistry at Kharkiv National University, Ukraine). They included various heterocyclic systems with substituents of different electronic nature, including various aliphatic fragments, amino acid residues, halogens, and others. The representative structure was cepharanthine (CEP), CAS Number 481-49-2 [23].

6

145 Molecular Docking

- 146 X-ray crystal structures of the corresponding proteins from the Protein Data Bank were
- 147 used for docking. Receptor-oriented docking was performed using the AutoDock Vina

148 program [24].

149 Chemistry

150 The synthesis of potentially active hit compounds from virtual screening and docking

151 experiments was carried out using previously developed methods. Hit2 [25], Hit3 Ta

152 Hit5 [26], Hit9, Hit10 [27], Hit13 [28], Hit7, Hit15 [29] were prepared (Fig. 1).

153

154 Fig 1. Potentially active hits selected as a result of virtual screening and docking155

156 All NMR spectra were recorded on a Varian MR-400 spectrometer with standard pulse 157 sequences operating at 400 MHz for ¹H NMR and 101 MHz for ¹³C NMR. For all NMR 158 spectra, DMSO-d₆ was used as the solvent. Chemical shift values are referenced to 159 residual protons ($\delta_{\rm H}$ 2.49 ppm) and carbons ($\delta_{\rm C}$ 39.6 ppm) of the solvent as an internal 160 standard. LC/MS spectra were recorded on an ELSD Alltech 3300 liquid 161 chromatograph equipped with a UV detector (λ_{max} 254 nm), API-150EX mass-162 spectrometer, and using a Zorbax SB-C18 column, Phenomenex (100×4 mm) Rapid 163 Resolution HT cartridge 4.6×30 mm, 1.8-Micron. Elution started with 0.1 M solution 164 of HCOOH in water and ended with 0.1 M solution of HCOOH in acetonitrile, using a 165 linear gradient at a flow rate of 0.15 mL/min and an analysis cycle time of 25 min.

166 In vitro anti-inflammatory activity in human neutrophils

For the *in vitro* studies, the synthesized compounds (**Fig. 1**) were dissolved in dimethyl sulfoxide (DMSO) to prepare stock solutions. The final concentration of DMSO in cell experiments did not exceed 0.5% and did not affect the measured parameters. Blood was taken from healthy human donors using a protocol approved by the Chang Gung Memorial Hospital review board. Neutrophils were isolated following the standard procedure [30].

173 The inhibition of superoxide anion generation (respiratory burst) was measured based 174 on ferricytochrome c reduction as previously described [31]. Briefly, preheated 175 neutrophils (6 \times 10⁵ cells·mL⁻¹) and 0.6 mg/mL ferricytochrome c solution were 176 treated with the tested compounds or DMSO (control) for 5 min. The cells were 177 activated with formyl-methionyl-leucyl-phenylalanine (fMLF, 100 nM)/cytochalasin 178 B (CB, 1 µg/mL) for 13 min. The absorbance was continuously monitored at 550 nm 179 using Hitachi U-3010 spectrophotometer with constant stirring (Hitachi Inc., Tokyo, 180 Japan). Calculations were based on the differences in absorbance with and without 181 superoxide dismutase (SOD, 100 U/mL) divided by the extinction coefficient for the 182 reduction of ferricytochrome c ($\varepsilon = 21.1/\text{mM}/10$ mm).

Elastase release (i.e., degranulation from azurophilic granules) was evaluated as described before [32]. Briefly, neutrophils were equilibrated with elastase substrate, MeO-Suc-Ala-Ala-Pro-Val-*p*-nitroanilide (100 μ M), at 37 °C for 2 min and then incubated with the sample for 5 min. Cells were activated by 100 nM fMLF and 0.5 μ g/mL CB for 13 min, and changes in the absorbance at 405 nm corresponding to

188 elastase release were continuously monitored. The results were expressed as the 189 percentage of the initial rate of elastase release in the fMLF/CB-activated drug-free 190 control system.

191 **Pseudotyped lentivirus assay**

192 Lentivirus experiments were approved by the Institutional Biosafety Committee 193 of Chang Gung University and performed according to our previous report [42]. Stable 194 hACE-2 overexpressed HEK293T cells were provided by Dr. Rei-Lin Kuo (Chang 195 Gung University) and maintained in DMEM containing 10 % FBS and 10 µg/mL 196 blasticidin. VSV-G pseudotyped lentivirus control (clone name: S3w.Fluc.Ppuro) and 197 SARS-CoV-2 S-protein expressing VSV-G pseudotyped lentiviruses (clone name: 198 nCoV-S-Luc-D614G and nCoV-S-Luc-B.1.617.2) were purchased from RNAi Core 199 Facility of Academia Sinica. hACE-2 overexpressed cells (1×10^4 cells/well) were 200 seeded on 96-well plates and incubated at 37 °C with 5% CO₂. Equal relative infection 201 units (RIU) (5 \times 10³ RIU/well= 0.5 RIU/cell) of pseudotyped lentiviruses were 202 pretreated with various concentrations of antiviral agents in DMEM containing 5% 203 FBS at 37 °C for 1 hour. The medium of ACE-2 overexpressed cells was replaced with 204 treated pseudotyped lentivirus and cultured for 24 h. Luciferase activity was measured 205 using a Luciferase Assay System (E2520, Promega) and recorded by a Fluorescence 206 Reader. Cepharanthine served as a positive control.

207 WST-1 viability assay

The potential cytotoxicity of the tested samples was evaluated by the WST-1 reduction assay in hACE-2-overexpressed HEK293T [40]. The hACE-2-overexpressed HEK293T cells (1×10^4 cells/well) were preincubated with DMSO or tested agents for 24 h. Then, the WST-1 reagent (M192427, Sigma-Aldrich, MO, USA) was added and incubated for 4 h at 37 °C. The absorbance at 405 nm was measured by a Multiska GO spectrophotometer (Thermo Fisher Scientific, MA, USA).

214

215 Statistical analysis

216 Results are expressed as mean \pm S.E.M. of two independent measurements 217 (pseudoviral anti-viral assay) or mean \pm S.E.M. of three independent measurements (anti-inflammatory assay). The 50% inhibitory concentration (IC_{50}) was calculated 218 219 from the dose-response curve obtained by plotting the percentage of inhibition versus 220 concentrations (linear function, Microsoft Office, anti-inflammatory assay). Statistical 221 analysis was performed using Student's *t*-test (Sigma Plot, Systat Software, Systat Software Inc., anti-inflammatory). Values with *P < 0.05, **P < 0.01, ***P < 0.001222 223 were considered statistically significant.

- 224
- 225 **Results**

226 In silico models and calculations

Studies of the bis-benzylisoquinoline alkaloid cepharanthine (CEP) against COVID-19 identified its significant antiviral and anti-inflammatory potential. However, the

229 precise mechanism of CEP is still under investigation [11, 12]. To model the 230 mechanism of cepharanthine's action on COVID-19, researchers focused on various 231 protein targets available in the Protein Data Bank (PDB). According to scientific 232 literature, one of the primary mechanisms of CEP's action against COVID-19 is its 233 binding to ACE2, which was validated by molecular dynamics (MD) simulations [33]. 234 Cepharanthine was selected as the representative structure to develop new molecules 235 with the potential to inhibit key viral pathways. The 3D crystal structure of the receptor 236 binding domain of the SARS-CoV-2 Omicron variant spike glycoprotein complex with 237 its receptor, human ACE2 (PDB: 7WBP), was chosen as the biological target. 238 We conducted a preliminary pharmacophore screening using the LigandScout suite to 239 identify suitable structures for further investigation. The receptor-binding domain of 240 the SARS-CoV-2 Omicron spike glycoprotein complex with the human ACE2 receptor 241 and the ligand NAG PDB 7WBP [34] was employed as a representative protein-ligand 242 structure for the study (Fig. 2).

243

Fig. 2. Receptor binding domain of SARS-CoV-2 Omicron spike glycoprotein complex with its receptor human ACE2 with ligand NAG (A), the structure of cepharanthine CEP (D) and its pharmacophore (C).

247

The pharmacophore model CEP was used as a search query to identify compounds targeting the binding site of the biological target. Virtual screening (VS) of a molecular database (DB_KSM) according to the pharmacophore identified in the previous step

resulted in identifying several compounds that could be promising in the fight against
COVID-19. Based on matching with the pharmacophore, 23 compounds were selected
for further study (Fig. 3).

254

Fig 3. The structures with possible activity against SARS-COV2 according to VS
results of DB KSM database.

257

258	The docking of these molecules to the receptor-binding domain of the SARS-CoV-2
259	Omicron spike glycoprotein complex with the human ACE2 receptor (PDB 7WBP)
260	was performed. Their binding affinity parameters were calculated. The binding affinity
261	scores (BAS) and binding energies (BE, kcal/mol) of the docked hit compounds, along
262	with the co-crystallized ligand (NAG) and CEP, are presented in Table 1.

263	Table 1. Affinity parameters of hit structures	(complex PDB 7WBP)	

Mol	BAS	BE (kcal/mol)	Mol	BAS	BE (kcal/mol)
NAG	-2.04	-7.10	СЕР	-17,54	-7,30
Hit1	-6,93	-6,60	Hit13	-17.71	-9.10
Hit2	-11.14	-8.50	Hit14	-6,88	-6,50
Hit3	-15.91	-7.90	Hit15	-10.14	-9.10
Hit4	-6,78	-7,10	Hit16	-6,56	-7,10
Hit5	-12.41	-7.60	Hit17	-6,38	-6,90
Hit6	-5,86	-7,00	Hit18	-5,85	-6,70
Hit7	-7.56	-8.60	Hit19	-5,49	-6,80
Hit8	-7,00	-6,90	Hit20	-7,13	-7,00

It is made available under a CC-BY 4.0 International license .							
Hit9	-10.78	-8.50	Hit21	-6,67	-6,56		
Hit10	-13.89	-8.40	Hit22	-2,54	-6,10		
Hit11	-6,48	-6,90	Hit23	-4,34	-5,85		
Hit12	-5,26	-7,00					

medRxiv preprint doi: https://doi.org/10.1101/2024.11.06.24316825; this version posted November 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

264

As shown in **Table 1**, eight compounds (**Hit2**, **Hit3**, **Hit5**, **Hit7**, **Hit9**, **Hit10**, **Hit13**, and **Hit15**) exhibited binding energies exceeding the absolute values of the representative cepharanthine (CEP) structure. These compounds were selected for further molecular docking studies with target proteins identified in the literature as potential pharmacological targets of cepharanthine [33].

270 For the calculations, hub targets for the potential pharmacological mechanism of CEP 271 against COVID-19 were selected (Table 2). In the study [33], "network pharmacology" 272 combined with RNA sequencing, molecular docking, and MD modeling was used to 273 identify hub targets and potential pharmacological mechanisms of cepharanthine 274 (CEP) against COVID-19. Nine key hub genes (ACE2, STAT1, SRC, PIK3R1, HIF1A, 275 ESR1, ERBB2, CDC42, and BCL2L1) were identified. Based on these data, we 276 performed docking studies of the home library to the hub targets from the Protein Data 277 Bank [22] described above.

278

Table 2. Hub-targets and potential pharmacological mechanisms of action of cepharanthine (CEP) against COVID-19

Target	Designation	Classification
--------	-------------	----------------

1BF5	Tyrosine phosphorylated STAT-1/DNA complex	Gene regulation/DNA
1A07	C-SRC (SH2 domain) complexed with ace- malonyl tyr-glu-(N,N-dipentyl amine)	Complex (transferase/peptide)
2 IUI	Crystal structure of the PI3-kinase p85 N- terminal SH2 domain in complex with PDGFR phosphotyrosyl peptide	Transferase
1H2K	Factor Inhibiting HIF-1 alpha in complex with HIF-1 alpha fragment peptide	Transcription activator/inhibitor
2AJF	Structure of SARS coronavirus spike receptor-binding domain complexed with its receptor	Hydrolase / viral protein
1A52	Estrogen receptor alpha ligand-binding domain complexed to estradiol	Receptor
2A91	Crystal structure of ErbB2 domains 1-3	Signaling protein, transferase, membrane protein
7S0Y	Structures of TcdB in complex with Cdc42	Hydrolase
7JGW	Crystal structure of BCL-XL in complex with compound 1620116, crystal form 1	Apoptosis

281

Docking was performed using AutoDock Vina with CEP and the studied molecules. 282

The results of molecular docking and binding energies of the molecules are presented 283

- in Table 3. 284
- 285

Table 3. Molecular docking binding energy results of hub genes with CEP and 286

287 hit-molecules

3 Hit15	Hit13	Hit10	Hit9	Hit7	Hit5	Hit3	Hit2	CEP ^a	REF ^a	Target
---------	-------	-------	------	------	------	------	------	------------------	------------------	--------

		It is i	made availal	ble under a	CC-BY 4.0 li	nternational	license.			
1BF5	-6.0	-9.8	-9.1	-8.7	-9.3	-8.9	-9.0	-9.0	-8.7	-8.9
1A07	-7.0	-7.4	-8.1	-7.0	-8.3	-7.3	-8.8	-7.2	-8.2	-7.6
2IUI	-6.2	-9.5	-9.2	-9.3	-9.8	-8.7	-9.2	-8.9	-9.2	-8.2
1H2K	-4.3	-8.8	-8.1	-9.2	-8.4	-8.0	-8.9	-7.9	-8.6	-8.0
2AJF	-5.6	-11.1	-9.7	-9.3	-9.2	-8.8	-10.0	-8.7	-9.6	-9.0
1A52	-10.4	-8.2	-9.3	-8.4	-10.1	-8.2	-9.2	-9.4	-9.4	-8.7
2A91	-6	-9.7	-9.8	-8.4	-8.2	-8.9	-10.0	-8.8	-8.9	-8.2
7S0Y	-6.7	-8.3	-9.4	-8.1	-8.5	-9.5	-8.4	-9.1	-8.7	-7.4
7JGW	-10.4	-8.9	-8.9	-7.6	-8.5	-8.2	-8.4	-9.5	-9.2	-8.6

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.06.24316825; this version posted November 11, 2024. The copyright holder for this

^a Data from [33]

289

The molecular docking results showed a good potential for inhibition of Target 2AJF, the spike receptor-binding domain of SARS-CoV-2, in complex with its receptor and a set of targets responsible for modulating the immune response.

Additionally, we utilized the SwissTargetPrediction resource further to evaluate the most likely macromolecular targets for CEP (**Fig. 4**) and the new molecules to assess the possibility of using multiple therapeutically relevant targets for the studied compounds, as most bioactive molecules have more than one target [35].

297

Fig 4. The most probable macromolecular targets of CEP, suggested by the SwissTargetPrediction resource [20]

300

The identified biological targets for CEP included the family A G protein-coupled
 receptors – cell surface proteins that detect molecules outside the cell and activate

303 cellular included responses. including immune Thev also the responses. 304 electrochemical transporters and ligand-gated ion channels responsible for signal 305 molecule transport regulated by membrane potential or ion flow. The biological targets 306 of the new hit compounds are presented as an aggregate bar chart (Fig. 5), reflecting 307 the contribution of each category.

308 Fig 5. Biological target pool of the new hit molecules proposed by the
309 SwissTargetPrediction resource [20]

310

The primary predicted target categories for the new hit molecules, as proposed by the SwissTargetPrediction resource, were the kinase/family A G / B G protein-coupled receptors/protease.

314 Table 4 presents the categories of biological targets for the new hit molecules: a) 315 Targets responsible for modulating the immune response, which may be one of the 316 mechanisms contributing tissue inflammation in COVID-19 to (kinases 317 (phosphotransferases) / protein-coupled receptor A G /B G family); b) Targets from 318 the protease category, which may be involved in inhibiting key pathways of viral 319 replication.

320

321 Table 4. Categories of biological targets for pharmacological action against 322 SARS-COV-2 used in the study

Target	Designation	Classification
--------	-------------	----------------

4E4L	AK1 kinase (JH1 domain) in complex	Transferase/kinase
4D1S	Crystal structure of JAK2 kinase	Transferase/kinase
4Z16	Crystal Structure of the Jak3 Kinase Domain	Transferase/kinase
1ALU	Human Interleukin-6	Cytokine
7WOF	Crystal structure of SARS-CoV-2 Mpro	Viral protein/protease
7LLZ	Crystal structure of SARS-CoV-2 papain-like protease (PLpro)	Viral protein/protease

323

The results of the molecular docking, the energy characteristics of the binding affinity 324 in kcal/mol (A), and the binding affinity score (BAS) of the studied molecules for the 325

main predicted categories of biological targets are presented in Table 5. 326

327

Table 5. Results of molecular docking: Energy characteristics of binding affinity 328

329 in kcal/mol (A) and binding affinity score (BAS) of the studied molecules for the

main predicted categories of biological targets 330

Biolog targ	0	Ligand	Hit2	Hit3	Hit5	Hit7	Hit9	Hit10	Hit13	Hit15	СЕР
4E4L	A	-11.0	-5.8	-6.9	-6.8	-8.4	-6.5	-6.4	-8.3	-6.3	-5.9
	BAS	-18.4	-14.1	-13.0	-13.6	-21.7	-29.0	-28.4	-13.8	-16.4	-10.7
4D1S	Α	-10.7	-8.4	-9.6	-9.3	-9.5	-9.5	-9.5	-8.5	-9.4	-5.5
	BAS	-13.7	-14.6	-14.3	-11.0	-14.4	-17.6	-18.9	-6.2	-2.3	-10.6
4Z16	A	-8.2	-8.7	-9.5	-9.0	-6.9	-9.8	-9.4	-9.3	-9.2	-10.4
	BAS	-10.9	-18.3	-12.1	-14.7	-12.4	-13.9	-12.5	-13.3	-10.2	-10.6
1ALU	A	-4.6	-5.1	-5.9	-6.1	-6.0	-5.8	-6.1	-6.9	-5.7	-4.5
	BAS	-12,.5	-2.1	-16.8	-7.6	-15.3	-2.1	-3.2	-7.9	-1.0	-2.0

7WO	A	-6.8	-6.4	-6.3	-6.7	-7.1	-7.6	-7.6	-7.7	-7.9	-4.9
	BAS	-14.6	-10.5	-8.8	-13.5	-6.5	-8.8	-5.4	-1.4	-13.6	9.3
7LL2	A	-8.9	-7.8	-8.1	-8.5	-8.8	-8.0	-8.0	-8.4	-7.9	-7.3
	BAS	-20.0	-12.5	-1.1	-12.5	-16.7	-3.9	-7.3	-7.4	-13.2	-15.2

331

The tested molecules showed potential inhibition of Target 4Z16 (Jak3), a domain of the Janus kinase JAK3, a representative of tyrosine kinases, cytoplasmic enzymes involved in mediating intracellular signaling from cytokine receptors, which are responsible for inflammation processes [36]. Hit molecules also showed potential inhibition of SARS-COV-2 proteases Mpro and PLpro.

337 Several ADME parameters were calculated to evaluate the suitability of the identified 338 compounds in terms of drug-like properties, including chemical absorption, 339 distribution, metabolism, and excretion, which play a crucial role in determining 340 potential drug molecules. Table 6 presents parameters such as lipophilicity (clogP), 341 topological polar surface area (TPSA), molecular weight (parameter SIZE, g/mol), 342 solubility (LogS), fraction of sp3 carbon atoms (Fraction Csp3), flexibility, and optimal 343 values of these parameters. The studied molecules conform to the drug-likeness 344 properties.

345

346 Table 6. Drug-likeness properties of selected hits

Name	Log P _{o/w}	SIZE (g/mol)	TPSA, Å ²	LogS	Fraction C (sp ³)	Flexibility
	-0.7 <x<5.0< td=""><td>150<x<500< td=""><td>20<x<130< td=""><td>0<-X<6</td><td>0.25<x<1< td=""><td>0<x<9< td=""></x<9<></td></x<1<></td></x<130<></td></x<500<></td></x<5.0<>	150 <x<500< td=""><td>20<x<130< td=""><td>0<-X<6</td><td>0.25<x<1< td=""><td>0<x<9< td=""></x<9<></td></x<1<></td></x<130<></td></x<500<>	20 <x<130< td=""><td>0<-X<6</td><td>0.25<x<1< td=""><td>0<x<9< td=""></x<9<></td></x<1<></td></x<130<>	0< - X<6	0.25 <x<1< td=""><td>0<x<9< td=""></x<9<></td></x<1<>	0 <x<9< td=""></x<9<>
Hit2	3.51	504.60	121.65	-4.82	0.26	12

	It is	made available unde	er a CC-BY 4.0 Interna	ational license .		
Hit3	5.09	442.51	90.02	-5.71	0.23	9
Hit5	4.35	462.93	90.02	-6.00	0.20	9
Hit7	5.00	389.47	97.34	-5.72	0.14	5
Hit9	3.74	438.48	137.16	-4.98	0.14	7
Hit10	3.61	450.51	116.39	-4.89	0.18	8
Hit13	1.97	435.41	122.28	-3.70	0.09	9
Hit15	3.22	473.57	151.90	-4.63	0.25	9

perpetuity

medRxiv preprint doi: https://doi.org/10.1101/2024.11.06.24316825; this version posted November 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

347

In vitro models 348

SARS-CoV-2 spike/ACE2 pseudovirus neutralization assay 349

The S-protein and ACE2 receptor play an essential role in the early phases of 350 351 coronavirus infection [37]. The established binding assay is based on measuring luciferase activity and utilizes stable hACE-2 overexpressed HEK293T cells and 352 353 SARS-CoV-2 S-protein expressing VSV-G pseudotyped lentiviruses. Omicron 354 B1.1.529 SARS-CoV-2 coronavirus subtype was chosen as the most related subtype to 355 the current variant. It is well known that the mutations increase the infectivity of the 356 COVID-19 virus [38]. The cytotoxicity against hACE2-293T cells was tested, and the 357 results revealed no toxicity (Table 7).

358

359 Table 7. Effects of synthetic compounds on hACE-2 overexpressed HEK293T 360 viability

Compound	Cell viability (%) ^a
Hit13	105.92

It is made available under a CC-BY 4.0 International license	е.
--	----

Hit9	103.83
Hit3	95.82
Hit 7	99.47
Hit10	96.57
Hit5	95.19
Hit15	97.33
Hit2	100.00

- 361 ^a Percentage of cell at 10 μ V(n = 1). Control group (DMSO)
- 362 Next, the SARS-CoV-2 S-protein and ACE2 binding assay results showed activity of

363 Hit15 with 43.0% inhibition at 10 μ M (Table 8). The compound possesses sulforyl

and pyrimidone moiety that may be responsible for the observed activity [39, 40].

365

- 366 **Table 8. Effect of synthetic compounds in the pseudovirus neutralization assay of**
- 367 Omicron variants (SARS-CoV-2 Spike protein pseudotyped lentivirus type).

Compound	Inh%ª
Hit13	19.78 ± 8.29
Hit9	2.14 ± 10.15
Hit3	10.46 ± 5.69
Hit 7	22.12 ± 14.37
Hit10	14.25 ±9.76
Hit5	0.08 ± 6.23
Hit15	43.00 ± 0.80
Hit2	29.56 ± 13.34
Cepharanthine	97.33 ±0.08

³⁶⁸ ^a Percentage of inhibition (Inh.%) at 10 μ M. Results are presented as mean ± S.E.M. (n = 2). Control 369 group (DMSO). SARS-CoV-2 preudovirus strain: Omicron (B.1.1.529).

370

371 In the pseudovirus neutralization assay, cepharanthine showed 97.3% inhibition 372 at 10 μ M and IC₅₀ 1.07 \pm 0.24 μ M. The antiviral potential of HIT15 and cepharanthine were in agreement with the reported data [41]. They indicated that both compounds 373 374 may suppress infection of SARS-CoV-2 pseudovirus in hACE2-overexpressed host 375 cells and may interfere with the S-protein/ACE2 binding. Previous research suggested 376 that reducing the activity of TMPRSS2 using plant secondary metabolites could help 377 manage COVID-19. TMPRSS2 is crucial for the virus entry stage by priming the 378 S-protein of SARS-CoV-2, which facilitates the fusion of viral and host cell 379 membranes. In an *in vitro* molecular docking study, cepharanthine interacted well with 380 the TMPRSS2 and SARS-CoV-2 S-protein [43]. These data bode well with the docking 381 result for cepharantine (Table 3) in the SARS-CoV-2 S-protein/ACE2 binding pocket. 382 The anti-inflammatory activity was studied in vitro in a model of inhibition of 383 superoxide anion release and elastase in human neutrophils. The effect of new 384 molecules on superoxide anion generation and elastase release in activated human 385 neutrophils was studied (Table 9). Superoxide anion generation and elastase release 386 were induced by FMLP/CB and measured respectively. All data are expressed as mean \pm S.E.M. (n = 3-4). *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the 387 388 control.

389

390 Table 9. Effects of compounds on superoxide anion generation and elastase release

391 in fMLF/CB-induced human neutrophils

Compound	Su	Superoxide anion				Elas	tase rele	ease	
	IC ₅₀ (μΜ) ^a	Inh%	0		IC ₅₀ (μ	M) ^a	In	h%	
Hit13 ^b	>100	-4.72 ±	6.46		19.73 ±	2.39	113.52	± 8.51	***
Hit9 ^b	>100	-0.55 ±	0.96		17.12 ±	0.19	122.94	± 5.95	***
Hit10 ^b	>100	-0.40 ±	2.56		18.78 ±	4.25	73.21	± 5.87	***
Hit15 ^b	$\begin{array}{c} 1.43 \pm \\ 0.18 \end{array}$	100.41 ±	0.28	***	1.28 ±	0.33	114.63	± 1.32	***
Hit5 ^c	>50	0.02 ±	1.67		>50		26.06	± 3.28	**
Hit3 ^d	>10	-0.61 ±	0.43		>10		22.11	± 6.04	*
Hit7 ^d	>10	7.19 ±	2.87		>10		34.27	± 2.90	***
Hit2 ^d	>10	5.99 ±	2.80		>10		7.60	± 4.78	***
LY294002e	1.76± 0.28	96.14 ±	1.79	***	2.23 ± 0.15		84.59	± 2.86	***

Results are presented as mean \pm S.E.M. (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control (DMSO).

^a Concentration necessary for 50% inhibition (IC₅₀).

^b Percentage of inhibition (Inh%) at 100 µM. Compounds' solubility was 50 mM.

^c Percentage of inhibition (Inh%) at 50 µM. Compound solubility was 25 mM.

^d Percentage of inhibition (Inh%) at 10 µM. Compounds' solubility is 5 mM.

^e Positive control.

392

Experimental results showed that Hit13, Hit9, and Hit10 moderately affected elastase 393

394 release. Hit15 showed good anti-inflammatory activity with IC₅₀ 1.76 and 2.23 μ M in

395 both superoxide anion generation and elastase release assays in fMLF/CB-induced

396 human neutrophils, respectively. The Hit15 molecule has good potential for further

development to treat COVID-19. 397

398

399 CONCLUSION

400 A virtual in silico screening and receptor-oriented docking was conducted on three-401 dimensional structural models of active sites in biological molecules involved in the 402 mechanisms of SARS-CoV-2 impact on the body, using cepharanthine as a representative structure. Several hit molecules were identified, characterized by 403 404 binding energies with the active sites of the targets at levels comparable to or exceeding 405 those of the representative cepharanthine structure. Receptor-oriented docking 406 revealed that these hit molecules have the potential to inhibit SARS-CoV-2 proteases 407 Mpro and PLpro, which play a crucial role in viral replication mechanisms, as well as 408 to inhibit Janus kinase (Jak3), which mediates intracellular signal transduction and is 409 responsible for inflammatory processes.

The hit molecules were evaluated *in vitro* for anti-inflammatory activity. They were demonstrated by assessing their inhibitory effects on elastase release in human neutrophils and the generation of superoxide anions, a characteristic of antiinflammatory action. It was shown that the 2-((5-((4-isopropylphenyl)sulfonyl)-6-oxo-1,6-dihydropyrimidin-2-yl)thio)-N-(3-methoxyphenyl)acetamide (**Hit15**) exhibited potent anti-inflammatory activity. Several other molecules also demonstrated moderate effects on elastase release.

417

418 Author Contributions

419 V.A.G., V.V.I. - Conceptualization,

- 420 Y.-L.C., S.-Y.F., L.V.Y., O.M.K. Data Curation
- 421 V.A.G, O.M.K. Project Administration
- 422 V.V.I., A.B.Z., D.O.A. Software
- 423 O.M.K., T.-L.H. Supervision.
- 424 L.V.Y., V.V.I., S.M.K., M.E.-S., M.K., O.O.M. Writing original draft
- 425 V.A.G. Writing Review & Editing;
- 426 T.-L.H., O.M.K. Funding Acquisition
- 427 All authors have read and agreed to the published version of the manuscript.
- 428

429 Acknowledgement

430 VVI, ABZ, SMK, L.V.Y and O.M.K. express their gratitude to the National 431 Research Foundation of Ukraine (https://nrfu.org.ua/en/fundraising en/) for financial 432 support (grant No. 87/0062 (2021.01/0062) "Molecular design, synthesis and screening" 433 of new potential antiviral pharmaceutical ingredients for the treatment of infectious 434 diseases COVID-19"). This research was supported by grants from the National 435 Science and Technology Council (https://www.nstc.gov.tw) (NSTC 113-2321-B-255-436 001, 113-2321-B-182-003, 112-2321-B-182-003, 112-2321-B-255-001, 111-2320-B-255-006-MY3, and 111-2321-B-255-001 granted to T.L.H.; and 113-2320-B-037-023, 437 438 112-2320-B-037-012, and 111-2320-B-037-007 granted to M.K.), Chang Gung 439 University of Science and Technology (https://english.cgust.edu.tw) (ZRRPF3L0091 440 ZRRPF3N0101) granted to T.L.H., Chang Gung Memorial Hospital and (https://www.cgmh.org.tw/eng) (CMRPF1P0051-3, CMRPF1P0071-3) granted to 441

medRxiv preprint doi: https://doi.org/10.1101/2024.11.06.24316825; this version posted November 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . T.L.H., 442 Research Foundation and Kaohsiung Medical University 443 (https://www.kmu.edu.tw/index.php/en-gb/research) (KMU-Q113011) granted to 444 M.K., Taiwan. We thank Prof. T. Langer for the opportunity to work with the 445 LigandScout suite.

- 446 The funders had no role in the study design, data collection, analyses, decision
- to publish, or manuscript preparation.
- 448
- 449 Institutional Review Board Statement
- 450 The study was conducted according to the guidelines of the Declaration of Helsinki
- 451 and approved by the Institutional Review Board of Chang Gung Memorial Hospital
- 452 (Registration number: IRB No.: 202301906A3C501), 1st August to 30th September
- 453 2024 was the recruitment period for this study.
- 454

455 Informed Consent Statement

- 456 Informed consent written and signed by donors was obtained from all subjects involved
- 457 in the study. No minors were included.
- 458

459 Data Availability Statement

460 All data are fully available without restriction. All relevant data are within the 461 manuscript.

462

463 **Conflicts of Interest**

464 There are no competing interests to declare.

466 **References**

- 1. World Health Organization. (2020). Corticosteroids for COVID-19. WHO-467 468 2019-nCoV-Corticosteroids-2020.1-eng.pdf. 469 https://iris.who.int/bitstream/handle/10665/334125/WHO-2019-nCoV-470 Corticosteroids-2020.1-eng.pdf?sequence=1. 471 2. Inpatient Considerations in COVID-19 Treatment and Prevention. US 472 Pharm. 2022;47(4):HS-1-HS-7. 473 3. Zagaliotis P, Petrou A, Mystridis GA, Geronikaki A, Vizirianakis IS, Walsh TJ. 474 Developing New Treatments for COVID-19 through Dual-Action 475 Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling. Int J Mol Sci. 2022 Jul 20;23(14):8006. doi: 476 10.3390/ijms23148006. PMID: 35887353; PMCID: PMC9325261. 477 4. Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S. Emerging 478 479 SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and 480 Vaccine Efficacy. Vaccines (Basel). 2021 Oct 18;9(10):1195. doi: 481 10.3390/vaccines9101195. PMID: 34696303; PMCID: PMC8537675 482 5. Aleem A, Akbar Samad AB, Vagar S. Emerging Variants of SARS-CoV-2 and 483 Novel Therapeutics Against Coronavirus (COVID-19). 2023 May 8. In: 484 StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing: 2024 Jan-. 485 PMID: 34033342. 486 6. World Health Organization. (2020). Clinical care for severe acute respiratory
- 487 infection: toolkit: COVID-19 adaptation. World Health Organization.

488 https://iris.who.int/bitstream/handle/10665/331736/WHO-2019-nCoV-

- 489 SARI_toolkit-2020.1-eng.pdf
- 490 7. Rohilla S. Designing therapeutic strategies to combat severe acute respiratory
 491 syndrome coronavirus-2 disease: COVID-19. Drug Dev Res. 2021;82:12–26
- 492 8. Lai KH, Chen YL, Lin MF, El-Shazly M, Chang YC, Chen PJ. Lonicerae
- 493 Japonicae Flos Attenuates Neutrophilic Inflammation by Inhibiting Oxidative
- 494 Stress. Antioxidants (Basel). 2022 Sep 9;11(9):1781. doi:
- 495 10.3390/antiox11091781. PMID: 36139855; PMCID: PMC9495740
- 496 9. Li J, Zhang K, Zhang, y. *et al.* Neutrophils in COVID-19: recent insights and
 497 advances. Virol J 20, 169 (2023). <u>https://doi.org/10.1186/s12985-023-02116-</u>
 498 w/
- 499 10.Anti-inflammatory, antiallergic and COVID-19 protease inhibitory activities of
- 500 phytochemicals from the Jordanian hawksbeard: identification, structure–
- 501 activity relationships, molecular modeling and impact on its folk medicinal
- 502
 uses.
 RSC
 Adv.,
 2020,10,
 38128-38141.

 503
 https://pubs.rsc.org/en/content/articlelanding/2020/ra/d0ra04876c
- 11.Fan H, He ST, Han P, Hong B, Liu K, Li M, Wang S, Tong Y. Cepharanthine:
 A Promising Old Drug against SARS-CoV-2. Adv Biol (Weinh). 2022
 Dec;6(12):e2200148. doi: 10.1002/adbi.202200148. Epub 2022 Jul 1. PMID:
 35775953; PMCID: PMC9350037
- 508 12.Xia B, Zheng L, Li Y, Sun W, Liu Y, Li L, Pang J, Chen J, Li J, Cheng H. The
 509 brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods,
- 510 and pharmacokinetics of cepharanthine: a potential small-molecule drug against

	perpetuity. It is made available under a CC-BY 4.0 International license .
511	COVID-19. Front Pharmacol. 2023 Jul 31;14:1098972. doi:
512	10.3389/fphar.2023.1098972. PMID: 37583901; PMCID: PMC10423819
513	13.Lengauer T, Rarey M. Computational methods for biomolecular docking.
514	Current Opinion in Structural Biology, Jun 1996, 6 (3): 402-6.
515	doi:10.1016/S0959-440X(96)80061-3. PMID 8804827
516	14.Ivanov VV, Lohachova KO, Kolesnik YV, Zakharov AB, Yevsieieva L V,
517	Kyrychenko AV, Langer T, Kovalenko SM, Kalugin ON. Recent advances in
518	computational drug discovery for therapy against coronavirus SARS-CoV-2.
519	ScienceRise: Pharmaceutical Science, 2023, DOI: 10.15587/2519-
520	4852.2023.290318
521	15.Jmol: an open-source Java viewer for chemical structures in 3D. Available
522	from: <u>http://www.jmol.org/</u>
523	16.DeLano WL. Pymol: An open-source molecular graphics tool. CCP4
524	Newsletter On Protein Crystallography 2002, 40: 82–92
525	17. Wolber G, Dornhofer AA, Langer T. Efficient overlay of small organic
526	molecules using 3D pharmacophores. J. ComputAided Mol. Des. 2006, 20
527	(12): 773–788. <u>https://doi.org/10.1007/s10822-006-9078-7</u>
528	18.LigandScout. Available from: <u>https://www.inteligand.com/ligandscout/</u>
529	19.Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and
530	computational approaches to estimate solubility and permeability in drug
531	discovery and development settings. Adv. Drug Deliv. Rev., 2012, 64: 4-17,
532	doi: 10.1016/j.addr.2012.09.019.
533	20.SwissTargetPrediction. Available from: <u>http://swisstargetprediction.ch/</u> .

28

- 534 21.DataWarrior. Available from: <u>https://openmolecules.org/datawarrior/</u>
- 535 22.Protein Data Bank, Database [Internet]. Available from: <u>www.rcsb.org</u>
- 536 23.Cepharanthine. PubChem, Database [Internet]. Available from:
- 537 <u>https://pubchem.ncbi.nlm.nih.gov/compound/10206</u>
- 538 24.AutoDock Vina. Available from: <u>https://autodock-</u>
- 539 vina.readthedocs.io/en/latest/docking_basic.html
- 540 25.Tkachenko OV, Vlasov SV, Kovalenko SM, Zhuravel IO, Chernykh VP.
- 541 Synthesis and the antimicrobial activity of 1-N-alkylated derivatives of 3-N-
- 542 substituted 1H-thieno[3,2-d]pyrimidine-2,4-diones. Journal of Organic and
- 543 Pharmaceutical Chemistry. 2013, 11(4): 15-21.
- 544 26.Kharchenko YV, Detistov AS, Orlov VD. Polycyclic systems containing 1,2,4-
- 545 oxadiazole ring. 3. 3-(1,2,4-oxadiazol-5-yl)pyridin-2(1H)-ones-synthesis and
- 546 prediction of biological activity. Visnik Kharkivs'kogo Natsional'nogo
 547 Universitetu im. V. N. Karazina. 2008; 820: 216-224.
- 548 27.Borisov AV, Detistov OS, Pukhovaya VI, Zhuravel' IO, Kovalenko SM.
- 549 Parallel liquid-phase synthesis of 5-(1H-4-pyrazolyl)-[1,2,4]oxadiazole
 550 libraries. J Comb Chem. 2009 Nov-Dec;11(6):1023-9. doi:
 551 10.1021/cc900070m. PMID: 19711964.
- 552 28.Konovalova IS, Geleverya AO, Kovalenko SM, Reiss GJ. One-pot synthesis
- and crystal structure of diethyl 2,6-dimethyl-4-(1-(2-nitrophenyl)-1H-1,2,3-
- 554 triazol-4-yl)-1,4-dihydropyridine-3,5-dicarboxylate, C21H23N5O6. Zeitschrift
- 555 für Kristallographie New Crystal Structures. 2023; 2 (238): 381-384.
- 556 <u>https://doi.org/10.1515/ncrs-2022-0573</u>

557	29. Vlasov SV, Kovalenko SM, Chernykh VP, Krolenko KY. Synthesis of 5
558	methyl-4-thio-6-(1,3,4-oxadiazol-2-yl)thieno[2,3-d]pyrimidines and their
559	antimicrobial activity study. Journal of Chemical and Pharmaceutical Research
560	2014; 6(6): 22-27.

30.Boyum A. Isolation of mononuclear cells and granulocytes from human blood.
Isolation of monuclear cells by one centrifugation, and of granulocytes by
combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest
Suppl. 1968; 97: 77-89.


565 31.Korinek M, Hsieh PS, Chen YL, Hsieh PW, Chang SH, Wu YH, Hwang TL.


- Randialic acid B and tomentosolic acid block formyl peptide receptor 1 in
 human neutrophils and attenuate psoriasis-like inflammation in vivo. Biochem
 Pharmacol. 2021; 190:114596.
- 569 32. Tsai YF, Chu TC, Chang WY, Wu YC, Chang FR, Yang SC, Wu TY, Hsu YM,
- 570 Chen CY, Chang SH, Hwang TL. 6-Hydroxy-5,7-dimethoxy-flavone 571 suppresses the neutrophil respiratory burst via selective PDE4 inhibition to 572 ameliorate acute lung injury. Free Radic Biol Med. 2017;106: 379-392.
- 573 33.Liu J, Sun T, Liu S, Liu J, Fang S, Tan S, Zeng Y, Zhang B, Li W. Dissecting
- 574 the molecular mechanism of cepharanthine against COVID-19, based on a
- 575 network pharmacology strategy combined with RNA-sequencing analysis,
- 576 molecular docking, and molecular dynamics simulation. Comput Biol Med.
- 577 2022 Dec;151(Pt A):106298. doi: 10.1016/j.compbiomed.2022.106298. Epub
- 578 2022 Nov 11. PMID: 36403355; PMCID: PMC9671524.

- 579 34.PDB 7WBP. Database [Internet]. Available from:
- 580 <u>https://www.rcsb.org/structure/7WBP</u>
- 581 35.Gfeller D, Michielin O, Zoete V. Shaping the interaction landscape of bioactive
- 582 molecules. Bioinformatics. 2013 Dec 1;29(23):3073-9. doi:
- 583 10.1093/bioinformatics/btt540. Epub 2013 Sep 17. PMID: 24048355.
- 584 36. Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies
- in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022
- 586 Mar;18(3):133-145. doi: 10.1038/s41584-021-00726-8. Epub 2022 Jan 5.
- 587 PMID: 34987201; PMCID: PMC8730299.
- 588 37.Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S
- et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
- 590 Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr
- 591 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
- 592 PMID: 32142651; PMCID: PMC7102627.
- 593 38.Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-
- 594 CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19
- 595 Virus. *Cell*. 2020/08/20/ 2020;182(4):812-827.e19.
- 596 doi:<u>https://doi.org/10.1016/j.cell.2020.06.043</u>
- 597 39.Negi M, Chawla PA, Faruk A, Chawla V. Role of heterocyclic compounds in
- 598 SARS and SARS CoV-2 pandemic. Bioorg Chem. 2020 Nov;104:104315. doi:
- 599 10.1016/j.bioorg.2020.104315. Epub 2020 Sep 24. PMID: 33007742; PMCID:
- 600 PMC7513919.


601	40.Eze FU, Ezeorah CJ, Ogboo BC, Okpareke OC, Rhyman L, Ramasami P,
602	Okafor SN, Tania G, Atiga S, Ejiyi TU, Ugwu MC, Uzoewulu CP, Ayogu JI,
603	Ekoh OC, Ugwu DI. Structure and Computational Studies of New Sulfonamide
604	Compound: {(4-nitrophenyl)sulfonyl}tryptophan. Molecules. 2022 Oct
605	31;27(21):7400. doi: 10.3390/molecules27217400. PMID: 36364227; PMCID:
606	PMC9654880.
607	41.Rogosnitzky M, Okediji P, Koman I. Cepharanthine: a review of the antiviral
608	potential of a Japanese-approved alopecia drug in COVID-19. Pharmacol Rep.
609	Dec 2020;72(6):1509-1516. doi:10.1007/s43440-020-00132-z
610	42. Chen YL, Chen CY, Lai KH, Chang YC, Hwang TL. Anti-inflammatory and
611	antiviral activities of flavone C-glycosides of Lophatherum gracile for COVID-
612	19. J Funct Foods. Feb 2023;101:105407. doi:10.1016/j.jff.2023.105407
613	43.He C-L, Huang L-Y, Wang K, et al. Identification of bis-benzylisoquinoline
614	alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products.
615	Signal Transduction and Targeted Therapy. 2021/03/23 2021;6(1):131.
616	doi:10.1038/s41392-021-00531-5


617







CH N H CH C	
1-(2-(2-fluorophenyl)-2-hydroxyethyl)-N-(4-	2-((5-((4-isopropylphenyl)sulfonyl)-6-oxo-
(furan-2-carboxamido)phenyl)-1H-1,2,3-	1,6-dihydropyrimidin-2-yl)thio)-N-(3-
triazole-4-carboxamide	methoxyphenyl)acetamide
Hit13	Hit15









Graphical Abstract